About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. (formerly Texas Biotechnology Corporation) is a global biopharmaceutical company engaged in the discovery, development and commercialisation of novel, synthetic small molecule compounds to address unmet medical needs. Our research and development programmes are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases.
Encysive has undergone a cultural evolution from a fully-fledged Research and Development boutique - headquartered in Houston, Texas - to a commercial entity. In preparation for the launch of THELIN┬« (sitaxentan sodium) in Europe, Encysive established a European commercial organisation - Encysive (UK) Limited - headquarted in London. Sales and marketing organisations have been set up in the United Kingdom, Ireland, Germany and France and are currently being developed in Italy, with other countries to follow. Furthermore, in Spain THELIN is represented by Praxis Pharmaceuticals, a marketing partner of Encysive. In mid 2007, the European organisation numbered approximately 35 field-based personnel, promoting THELIN across several European countries. Following a successful year, Encysive will continually expand its European team, including its office-based personnel in 2008. In August 2006, Encysive received a centralised marketing authorisation to market THELIN in all 27 member states of the EU. In 2007, THELIN was also approved in Australia and most recently in Canada.
THELIN - sitaxentan sodium - is an endothelin-A receptor antagonist (ETRA), a small molecule that blocks the action of endothelin, a potent mediator of blood vessel constriction and growth of smooth muscle in vascular walls. ETRAs may prove to be effective in the treatment of a variety of diseases where the regulation of vascular constriction is important. THELIN is 6500-fold more selective in targeting the endothelin-A than the endothelin-B receptor. Highly selective endothelin-A receptor antagonism has been shown to increase blood flow and reverse vasoconstriction in human clinical pharmacology studies.
THELIN is indicated for the treatment of patients with pulmonary arterial hypertension (PAH) classified as World Health Organization (WHO) functional class III to improve exercise capacity. Efficacy has been shown in primary/idiopathic PAH, and PAH associated with connective tissue disease (PAH-CTD). Moreover, THELIN is the first highly selective ETRA and the first once-daily oral treatment available for patients with PAH. THELIN was first launched in the United Kingdom and Germany in 2006, followed by commercialisation in The Netherlands, Ireland, France and Spain in 2007. Additional launches in EU member states will occur as local government approval for reimbursement is obtained.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a severe, rapidly progressive disease with diverse clinical and pathological features, affecting approximately 100,000-200,000 people in North America and Europe. The disease is characterised by high blood pressure and structural changes in the walls of the pulmonary arteries, the blood vessels that connect the right side of the heart to the lungs. As these arteries become increasingly constricted, blood flow and supply of oxygen may be inadequate to meet the bodyÔÇÖs demands. Since the heart must then pump harder to overcome the pulmonary vascular resistance, patients are susceptible to right-ventricular heart failure and premature death if untreated. Early medical treatment of PAH initially focused on vasodilator agents to counteract the blood vessel constriction. However, current treatments target specific cellular pathways involved in PAH.
To learn more about Encysive Pharmaceuticals please visit our web site: www.encysive.com Ôûá